Sinclair IS Pharma PLC  

(Public, LON:SPH)   Watch this stock  
Find more results for Stephen Sinclair
31.00
0.00 (0.00%)
Apr 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range     -
52 week 23.15 - 34.00
Open     -
Vol / Avg. 0.00/2.10M
Mkt cap 134.82M*
P/E     -
Div/yield     -
EPS -0.03*
Shares 434.91M
Beta     -
Inst. own     -
*GBP
Jul 7, 2014
Sinclair IS Pharma PLC Trading Update (Estimated) Add to calendar
May 1, 2014
Sinclair IS Pharma PLC General Meeting - 10:00AM GMT+1 - Add to calendar
Mar 25, 2014
Interim 2014 Sinclair IS Pharma PLC Earnings Release
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -9.63% -28.62%
Operating margin -9.49% -27.68%
EBITD margin - 11.92%
Return on average assets -3.13% -9.95%
Return on average equity -4.41% -14.10%
Employees 144 -
CDP Score - -

Address

1st Floor Whitfield Court 30-32 Whitfield Street
LONDON, ENG W1T 2RQ
United Kingdom - Map
+44-20-74676920 (Phone)
+44-20-74676930 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems. It has presence in five European markets and a marketing partner network across developed and emerging markets. On October 1, 2012, the Company announced that it had entered into a 100 year distribution agreement with Valeant Pharmaceuticals International Inc. for the distribution of injectable aesthetic dermal filler products Sculptra and New-Fill and the sub-distribution of Succeev in Western Europe. In March 2011, the Company launched FlammaSpray for the treatment of sunburn. In November 2013, Sinclair IS Pharma PLC announced the disposal of non-core products Effederm, Xclair, Salinum and SST. In January 2014, Sinclair IS Pharma PLC acquired Obvieline Laboratories SA. In January 2014, Sinclair IS Pharma PLC acquired Atlean, a dermal filler, from Stiefel the dermatology business of GSK.

Officers and directors

Christopher P. Spooner Chief Executive Officer, Executive Director
Age: 43
Alan Olby Chief Financial Officer
Jean-Louis Lamande Operations Finance Director
Christophe H. Foucher Chief Operating Officer, Executive Director
Patrick Khoukaz Head - European Operations and Global Aesthetics
Sarb Klair Head - Corporate Development
Nairn McMaster Head - Business Development
Stephen Redman Company Secretary, Legal Director
Grahame David Cook Non-Executive Independent Chairman of the Board
Robert Stuart Swanson Non-Executive Independent Director
Age: 51